<DOC>
	<DOCNO>NCT01153971</DOCNO>
	<brief_summary>This study evaluate efficacy safety MabThera combination chemotherapy , follow maintenance treatment MabThera . The anticipated time study treatment 1-2 year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Induction Maintenance Treatment With MabThera ( Rituximab ) Patients With Indolent B-Cell Nonfollicular Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient 1865 year age ; previously untreated indolent nonfollicular nonHodgkin 's lymphoma ; active disease ; &gt; =3 involve site . typical chronic lymphocytic leukemia ; malignancy within 3 year study , except basal squamous cell skin cancer cancer situ cervix ; systemic corticosteroid use &gt; 1 month ; significant cardiovascular disease ; central nervous system involvement ; hepatitis B C virus infection , HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>